CM-4307
- Generic Name
- CM-4307
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C21H16ClF3N4O3
- CAS Number
- 1130115-44-4
- Unique Ingredient Identifier
- 41XGO0VS1U
- Background
CM-4307 is under investigation in clinical trial NCT03602495 (Donafenib in 131I-Refractory Differentiated Thyroid Cancer).
- Indication
用于治疗既往未接受过全身系统性治疗的不可手术切除或转移性肝细胞癌患者。
- Associated Conditions
- -
- Associated Therapies
- -
Innovent to Present Clinical Data of Multiple Novel Molecules at ESMO Asia 2024
Innovent Biologics to present 10 clinical data on novel oncology molecules at ESMO Asia 2024, including updated Phase 1 results of IBI343 in pancreatic cancer.
Clinical study on conversion therapy of hepatocellular carcinoma
10% of HCC patients with ideal resection globally, 19.2% achieved R0 resection in recent year. Conversion therapy enabled 28% initially unresectable HCC patients to undergo R0 resection. Clinical trials show high conversion rates, but real-world conversion rate is 1.81%. Conversion surgery patients had longer operation times and hospital stays but comparable survival prognosis to direct surgery patients.
Gearing up for the European Society for Medical Oncology (ESMO24) Congress with OBiS
OBiS Insights pre-meeting ESMO24 report profiles 275 new, unapproved cancer drugs, classified as 40% antibody-based, 37% small molecule, and 23% mixed bag. The report excludes drugs not in abstract titles and will update during the conference. 43% of these drugs were discussed at recent ASCO24 meetings.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath